Johnson & Johnson (NYSE:JNJ) Shares Sold by Ropes Wealth Advisors LLC

Ropes Wealth Advisors LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 17.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 60,022 shares of the company’s stock after selling 13,063 shares during the quarter. Johnson & Johnson comprises about 1.8% of Ropes Wealth Advisors LLC’s investment portfolio, making the stock its 10th largest holding. Ropes Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $10,268,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Marathon Capital Management boosted its holdings in Johnson & Johnson by 4.6% in the third quarter. Marathon Capital Management now owns 27,264 shares of the company’s stock valued at $4,404,000 after purchasing an additional 1,200 shares in the last quarter. Castle Rock Wealth Management LLC boosted its holdings in Johnson & Johnson by 3.9% in the fourth quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock valued at $2,119,000 after purchasing an additional 479 shares in the last quarter. Blueshift Asset Management LLC boosted its holdings in Johnson & Johnson by 671.9% in the third quarter. Blueshift Asset Management LLC now owns 30,365 shares of the company’s stock valued at $4,904,000 after purchasing an additional 26,431 shares in the last quarter. Pallas Capital Advisors LLC boosted its holdings in Johnson & Johnson by 42.1% in the third quarter. Pallas Capital Advisors LLC now owns 68,839 shares of the company’s stock valued at $11,363,000 after purchasing an additional 20,404 shares in the last quarter. Finally, Achmea Investment Management B.V. lifted its stake in Johnson & Johnson by 1.6% in the third quarter. Achmea Investment Management B.V. now owns 240,368 shares of the company’s stock valued at $38,819,000 after buying an additional 3,829 shares during the last quarter. 68.78% of the stock is owned by hedge funds and other institutional investors.

NYSE:JNJ traded down $1.02 during trading hours on Friday, hitting $176.85. The company’s stock had a trading volume of 7,732,163 shares, compared to its average volume of 7,745,147. The business’s 50-day moving average is $177.92 and its two-hundred day moving average is $170.40. The company has a market capitalization of $465.36 billion, a PE ratio of 23.83, a PEG ratio of 2.91 and a beta of 0.66. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $0.07. The firm had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. Johnson & Johnson’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.59 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.2 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be issued a $1.13 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date is Monday, May 23rd. This represents a $4.52 annualized dividend and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio is 57.14%.

JNJ has been the subject of a number of research reports. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 30th. Raymond James boosted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their price objective for the company from $180.00 to $183.00 in a research note on Wednesday, March 16th. Credit Suisse Group upped their price target on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, Bank of America began coverage on Johnson & Johnson in a research note on Wednesday, March 2nd. They set a “neutral” rating for the company. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Buy” and a consensus price target of $188.57.

In other Johnson & Johnson news, insider William Hait sold 29,699 shares of the company’s stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Thibaut Mongon sold 23,681 shares of the company’s stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total value of $4,173,776.25. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by corporate insiders.

About Johnson & Johnson (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.